Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia

Current Medical Research and Opinion

Volumn 22, Issue 10, 2006, Pages 2037-2039

  Daskalopoulou, Stella S ^a   Mikhailidis, Dimitri P ^b,c  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Combination therapy; Ezetimibe; Guidelines; Liver function tests; Low density lipoprotein cholesterol; Rosuvastatin; Simvastatin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN;

CLINICAL TRIAL; DOSE RESPONSE; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; PRACTICE GUIDELINE; PROTEINURIA; REVIEW; SINGLE DRUG DOSE; TABLET FORMULATION; VASCULAR DISEASE;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG COMBINATIONS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PYRIMIDINES; SIMVASTATIN; SULFONAMIDES; TABLETS;

EID: 33750508749     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X148364     Document Type: Review

References (22)

1. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041-53
2. Smith SC Jr, Allen J, Blair SN, et al.; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72
3. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52
4. Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005;59:1377-86
5. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511-28
6. Ose L, Shah A, Davies MJ, et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin 2006;22:823-35
7. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
8. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
9. Pedersen TR, Faergeman O, Kastelein JJ, et al.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
10. de Lemos JA, Blazing MA, Wiviott SD, et al.; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
11. Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006;22:1123-31
12. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis N Engl J Med 2002;346:539-40
13. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005;111:3051-7
14. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006;97(8A):44C-51C
15. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(8A):52C-60C
16. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
17. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
18. Shepherd J, Wenger N, for the TNT Steering Committee and Investigators. Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: The Treating to New Targets (TNT) Study. American College of Cardiology 2006 Scientific Sessions; March 13, 2006; Atlanta, GA. Abstract 808-3
19. Athyros VG, Elisaf M, Papageorgiou AA, et al.; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
20. Youssef F, Gupta P, Mikhailidis DP, et al. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 2005;56:279-87
21. Fonseca FA, Ruiz A, Cardona-Munoz EG, et al.; DISCOVERY PENTA investigators. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value - an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 2005;21:1307-15
22. Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006;97:1602-6